<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02163291</url>
  </required_header>
  <id_info>
    <org_study_id>LPS-01-2013</org_study_id>
    <nct_id>NCT02163291</nct_id>
  </id_info>
  <brief_title>Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer</brief_title>
  <official_title>Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric cancer is the second cause of cancer related death and China has the most gastric
      cancer patients in the world. Although systemic strategies, including adjuvant chemotherapy,
      postoperative chemoradiotherapy, perioperative chemotherapy, have evolved and showed benefits
      these years, the prognosis of advanced gastric cancer is still not satisfactory. Optimal
      regimens and optimal method administration is still being found. Neoadjuvant chemotherapy has
      many advantages, including downstaging the tumor, increasing R0 rate, early eradicating of
      micrometastasis. In previous trials, combination of paclitaxel and s-1 has showed safety and
      tolerance in recurrent or metastatic gastric cancer. Using liposome as a carrier, paclitaxel
      has a better histocompatibility and cellular affinity, resulting a improved stability and
      reduced toxicity. In this phase II trial, we are going to study the safety and feasibility of
      paclitaxel liposome plus s-1 as neoadjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Pathology is usually reported 1 week after operation.The result of Pathological complete response rate will be accessed after all of the 30 participants operated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Object Response Rate</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Object Response Rate(ORR) is defined as the percentage of CR and PR among all of the participants under best overall outcome evaluation .Pathology is usually reported 1 week after operation.The result of Object Response Rate will be accessed after all of the 30 participants operated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Disease Control Rate(DC R) is defined as the percentage of CR+PR+SD among all of the participants under best overall outcome evaluation .Pathology is usually reported 1 week after operation.The result of Disease Control Rate will be accessed after all of the 30 participants operated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Eventss a Measure of Safety and Tolerability</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants will be followed during all the s a Measure of Safety and Tolerability4 circles of chemotherapy ,an expected average of 12 weeks.Number of participants with Adverse Events will calculated as a Measure of Safety and Tolerability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 rate, surgical morbidity and mortality</measure>
    <time_frame>2 weeks</time_frame>
    <description>The results of R0 rate, surgical morbidity and mortality will be accessed after operation ,participants will be followed for the duration of hospital stay, an expected average of 2 weeks .</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Gastric Carcinoma</condition>
  <arm_group>
    <arm_group_label>paclitaxel liposome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1 plus paclitaxel liposome</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel liposome</intervention_name>
    <description>S-1 40 mg/m2 bid d1-14 po and paclitaxel liposome 175mg/m2 d1 intravenously infusion for 3 hours, every 3 weeks. After 2 cycles' treatment, if clinical response is complete response（CR）,partial regression（PR） or stable disease（SD）, another 2 cycles is administered and operation is performed after the total 4 cycles. If response is progressive disease（PD）, chemotherapy is stopped and operation is performed.</description>
    <arm_group_label>paclitaxel liposome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed gastric cancer

          -  Disease at clinical stage of resectable or potentially resectable(T3-4, N0-3, M0) by
             CT and endoscopic ultrasonography (EUS)

          -  Karnofsky performance status(KPS） ≥ 70

          -  No prior antitumor treatment is allowed, including chemotherapy, radiotherapy, immune
             therapy or target therapy

          -  Life expectancy more than 3 months

          -  Adequate organ function as defined below:White Blood Cell Count （WBC） ≥ 3.0*10^9/l,
             Absolute Neutrophil Count （ANC） ≥ 1.5*10^9/l, Hemoglobin ≥ 100 g/l, Platelets ≥
             100*10^9/l, Total Bilirubin （TBIL） ≤ 1.5mg/dl, Aspartate Aminotransferase（AST） and
             Alanine Aminotransferase(ALT) ≤ 2.5×ULN, Alkaline pPosphatase( ALP) ≤ 2.5×ULN, Renal
             Serum Creatinine &lt; 1.5mg/dl

          -  Adequate lung and heart function

        Exclusion Criteria:

          -  ≥ grade 2 neuropathy

          -  History of malignancy

          -  With uncontrolled central nervous system metastasis

          -  Concurrent disease or condition that would interfere with the subject's safety
             (including current active hepatic, biliary, renal, respiratory disease, acute
             infection, severe malnutrition, uncontrolled diabetes hypertension et al)

          -  Severely inadequate intake of water or diet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiafu Ji, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiafu Ji, M.D.</last_name>
    <email>jiafuj@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Haidian District, Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ziyu Li, M.D.</last_name>
      <email>ligregory369@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhaodong Xing, M.D.</last_name>
      <email>xingzhaodong2011@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jiafu Ji, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ziyu Li, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kan Xue, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhaodong Xing, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sfda.gov.cn/WS01/CL0001/</url>
    <description>Liposome-paclitaxel has been successfully studied and approved by the State Food and Drug Administration of China.</description>
  </link>
  <reference>
    <citation>Wang X, Zhou J, Wang Y, Zhu Z, Lu Y, Wei Y, Chen L. A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. Eur J Cancer. 2010 May;46(8):1474-80. doi: 10.1016/j.ejca.2010.02.002. Epub 2010 Mar 6.</citation>
    <PMID>20207133</PMID>
  </reference>
  <reference>
    <citation>Zhang Q, Huang XE, Gao LL. A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. Biomed Pharmacother. 2009 Sep;63(8):603-7. doi: 10.1016/j.biopha.2008.10.001. Epub 2008 Oct 31.</citation>
    <PMID>19019625</PMID>
  </reference>
  <reference>
    <citation>Chen L, Chen Q, Zhuang Z, Zhang Y, Tao J, Shen L, Shen X, Chen Z, Wang J, Zhu M, Wang H. Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer. Jpn J Clin Oncol. 2014 Mar;44(3):208-13. doi: 10.1093/jjco/hyt212. Epub 2014 Jan 22.</citation>
    <PMID>24453274</PMID>
  </reference>
  <reference>
    <citation>Huang D, Ba Y, Xiong J, Xu N, Yan Z, Zhuang Z, Yu Z, Wan H, Zhang Y, Deng T, Zheng R, Guo Z, Hu C, Wang M, Yu Z, Yao Y, Meng J. A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer. Eur J Cancer. 2013 Sep;49(14):2995-3002. doi: 10.1016/j.ejca.2013.05.021. Epub 2013 Jun 27.</citation>
    <PMID>23810466</PMID>
  </reference>
  <reference>
    <citation>Lee JJ, Kim SY, Chung HC, Lee KH, Song HS, Kang WK, Hong YS, Choi IS, Lee YY, Woo IS, Choi JH. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1083-90. doi: 10.1007/s00280-008-0818-3. Epub 2008 Sep 24.</citation>
    <PMID>18813927</PMID>
  </reference>
  <reference>
    <citation>Nakajo A, Hokita S, Ishigami S, Miyazono F, Etoh T, Hamanoue M, Maenohara S, Iwashita T, Komatsu H, Satoh K, Aridome K, Morita S, Natsugoe S, Takiuchi H, Nakano S, Maehara Y, Sakamoto J, Aikou T; Kyushu Taxol TS-1 Study Group. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer. Cancer Chemother Pharmacol. 2008 Nov;62(6):1103-9. doi: 10.1007/s00280-008-0693-y. Epub 2008 Mar 4.</citation>
    <PMID>18317763</PMID>
  </reference>
  <reference>
    <citation>Mochiki E, Ogata K, Ohno T, Toyomasu Y, Haga N, Fukai Y, Aihara R, Ando H, Uchida N, Asao T, Kuwano H; North Kanto Gastric Cancer Study Group. Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer. 2012 Jun 26;107(1):31-6. doi: 10.1038/bjc.2012.222. Epub 2012 May 22.</citation>
    <PMID>22617130</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <last_update_submitted>June 11, 2014</last_update_submitted>
  <last_update_submitted_qc>June 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Jiafu Ji</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>advanced gastric cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>safety</keyword>
  <keyword>feasibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

